Novartis Institutes for Bio Medical Research, Basel, Switzerland.
J Pharm Sci. 2014 Feb;103(2):752-9. doi: 10.1002/jps.23818. Epub 2013 Dec 20.
For very highly bound drugs (fu < 2%), the determination of the unbound fraction in plasma (fu) and a reliable estimation of protein-binding differences across species, populations, or concentrations is challenging. The difficulty is not mostly assay sensitivity but rather experimental bias. In equilibrium gel filtration (EGF)--opposite to the commonly used methods--the amount bound at a set-free concentration is determined. Therefore, signals and differences are bigger for more highly protein-bound drugs. We describe here a new experimental set-up developed to investigate binding in plasma and compare results with those obtained with standard methods for nine Novartis compounds. The method was then applied for two drugs for which it was challenging to obtain precise data with standard methods: midostaurin and siponimod. Despite the very high binding (fu ≤ 0.1%), precise estimation of up to 10-fold species differences relevant for safety assessments was possible. Evidence for the correctness of the data by comparison with other pharmacokinetics parameters is provided. Sensitivity to potential sources of experimental bias is compared with standard methods and advantages and disadvantages of the methods are discussed. In conclusion, EGF allows accurate determination of fu for very highly bound drugs and differentiation even above 99.9% of binding.
对于与蛋白结合非常紧密的药物(fu<2%),测定血浆中未结合部分(fu)并可靠评估不同物种、人群或浓度之间的蛋白结合差异极具挑战性。其难点并非主要在于检测灵敏度,而是实验偏差。在平衡凝胶过滤(EGF)中——与常用方法相反——测定在设定游离浓度下的结合量。因此,对于与蛋白结合更紧密的药物,信号和差异更大。我们在此介绍一种新的实验方法,用于研究血浆中的结合情况,并将结果与 9 种诺华化合物的标准方法进行比较。然后,该方法用于两种用标准方法难以获得精确数据的药物:米哚妥林和西尼莫德。尽管结合非常紧密(fu≤0.1%),但仍能精确估计高达 10 倍的安全评估相关的物种差异。通过与其他药代动力学参数进行比较,为数据的正确性提供了证据。还比较了该方法与标准方法对潜在实验偏差源的敏感性,并讨论了这些方法的优缺点。总之,EGF 可准确测定与蛋白结合非常紧密的药物的 fu,即使结合率超过 99.9%也能进行区分。